Anti-mitochondrial type M5 and anti-cardiolipin antibodies in autoimmune disorders: studies on their association and cross-reactivity
- PMID: 3608231
- PMCID: PMC1542609
Anti-mitochondrial type M5 and anti-cardiolipin antibodies in autoimmune disorders: studies on their association and cross-reactivity
Abstract
In a series of 42 positive sera, anti-mitochondrial type M5 antibodies (AMA-M5) were found most frequently in patients with SLE (24) and SLE-like syndromes. Patients with AMA-M5 displayed a higher prevalence of thrombocytopenia, thrombosis, biological false positive seroreactions for syphilis, lupus-like anticoagulant activity and anti-cardiolipin antibodies in comparison with a group of 43 SLE AMA-M5 negative patients. The strong association between anti-phospholipid and AMA-M5 antibodies cannot be explained entirely by cross-reactivity between these two groups of antibodies, as indicated by absorption experiments and studies using affinity purified antibody preparations. However, cardiolipin liposomes were able to reduce partially the titres of AMA-M5 sera, suggesting that a small population of AMA-M5 antibodies exists that cross-reacts with cardiolipin. The existence of this population was further substantiated by our demonstration that an IgM monoclonal antibody, from a patient with Waldenström's macroglobulinaemia, displayed both anti-cardiolipin and AMA-M5 activity, and AMA-M5 activity was completely inhibited by cardiolipin.
Similar articles
-
Anti-mitochondrial type 5 antibodies and anti-cardiolipin antibodies in systemic lupus erythematosus and auto-immune diseases.Clin Exp Immunol. 1987 Sep;69(3):485-92. Clin Exp Immunol. 1987. PMID: 3311494 Free PMC article.
-
A common anti-cardiolipin antibody idiotype in autoimmune disease: identification using a mouse monoclonal antibody directed against a naturally-occurring anti-phospholipid antibody.Clin Exp Immunol. 1989 Feb;75(2):211-6. Clin Exp Immunol. 1989. PMID: 2784733 Free PMC article.
-
Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome.Rheumatology (Oxford). 2003 Jul;42(7):893-9. doi: 10.1093/rheumatology/keg248. Epub 2003 Apr 16. Rheumatology (Oxford). 2003. PMID: 12730551
-
Anti-phospholipid antibodies.Clin Rheum Dis. 1985 Dec;11(3):591-609. Clin Rheum Dis. 1985. PMID: 3935364 Review. No abstract available.
-
Antiphospholipid antibodies: a review.Eur J Rheumatol Inflamm. 1984;7(1):5-8. Eur J Rheumatol Inflamm. 1984. PMID: 6443722 Review. No abstract available.
Cited by
-
Unusual manifestations of the antiphospholipid syndrome.Clin Rev Allergy Immunol. 2003 Aug;25(1):61-78. doi: 10.1385/CRIAI:25:1:61. Clin Rev Allergy Immunol. 2003. PMID: 12794262 Free PMC article. Review.
-
Prediction of Erosive Disease Development by Antimitochondrial Antibodies in Rheumatoid Arthritis.Arthritis Rheumatol. 2023 Jun;75(6):890-899. doi: 10.1002/art.42428. Epub 2023 Mar 29. Arthritis Rheumatol. 2023. PMID: 36580020 Free PMC article.
-
Anti-mitochondrial autoantibodies in systemic lupus erythematosus and their association with disease manifestations.Sci Rep. 2019 Mar 14;9(1):4530. doi: 10.1038/s41598-019-40900-3. Sci Rep. 2019. PMID: 30872710 Free PMC article.
-
Sera from patients with systemic lupus erythematosus demonstrate enhanced IgG binding to endothelial cells pretreated with tumour necrosis factor alpha.Rheumatol Int. 1995;15(3):99-105. doi: 10.1007/BF00302125. Rheumatol Int. 1995. PMID: 8588127
-
Patterns of gastrin secretion in patients with nonfunctioning pituitary adenomas.J Endocrinol Invest. 1991 Nov;14(10):861-5. doi: 10.1007/BF03347944. J Endocrinol Invest. 1991. PMID: 1802924
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical